Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy

Journal of Clinical Microbiology

Volumn 40, Issue 3, 2002, Pages 762-767

  De la Rosa, Rafael ^a   Pineda, Juan A ^a   Delgado, Juan ^a   Macías, Juan ^a   Morillas, Francisco ^a   Mira, José A ^a   Sánchez Quijano, Armando ^a   Leal, Manuel ^a   Lissen, Eduardo ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; SPAIN; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; FEMALE; HIV-1; HUMANS; INCIDENCE; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RISK FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; NASO HEXACANTHUS; RNA VIRUSES;

EID: 0036197581     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.40.3.762-767.2002     Document Type: Article

References (23)

1. Recurrent cutaneous leishmaniasis: A role for persistent parasites
2. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani
3. Injecting drug use as risk factor for visceral leishmaniasis in AIDS patients
4. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
5. The lipophosphoglycan of Leishmania donovani up-regulates HIV-1 transcription in T-cells through the nuclear factor κB elements
6. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi
7. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in HIV-infected patients
8. Influence of medical intervention on the presentation of AIDS defined by clinical episodes
9. Is leishmaniasis ever cured?
10. Specificity of a commercial indirect immunofluorescence technique in the diagnosis of visceral leishmaniasis in HIV-1 infected patients
11. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and atiretrovirai-experienced HIV-infected patients in Spain
12. Epidemiological of surveillance of leishmaniasis in HIV-1 infected individuals in Italy
13. + cells counts of 200 per cubic millimeter or less
14. Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-1 viral load after highly active antiretroviral therapy
15. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States, in the era of highly active antiretroviral therapy
16. Immune reconstitution in HIV- infected subjects treated with a potent antiretroviral therapy
17. Potential factors affecting adherence with HIV therapy
18. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment
19. Declining morbidity and mortality among patients with advanced immunodeficiency virus infection
20. Kala-azar comes to New York
21. Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain
22. Delayed hipersensitivity skin testing and anergy in a population of gay men
23. Leishmania-HIV interaction: Immunopathogenic mechanisms